[
  {
    "ts": null,
    "headline": "Why the Stock Price of This Cancer Screening Company Soared 17% Thursday",
    "summary": "Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion.",
    "url": "https://finnhub.io/api/news?id=9f275f37e2194c54e7dc47f9d790fa7d28961a79a1c2e9cb6cd4981cd3f04b40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763681385,
      "headline": "Why the Stock Price of This Cancer Screening Company Soared 17% Thursday",
      "id": 137566592,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Shares of Exact Sciences Corp. jumped after Abbott Laboratories announced a deal to acquire the cancer screening test maker for about $21 billion.",
      "url": "https://finnhub.io/api/news?id=9f275f37e2194c54e7dc47f9d790fa7d28961a79a1c2e9cb6cd4981cd3f04b40"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron",
    "summary": "↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares closed up nearly 6.5%. ↘️Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.",
    "url": "https://finnhub.io/api/news?id=ca40a6252ab1270147bbf92f5beb6ed8ac409575b6400a168a7846e58af6bc29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763676342,
      "headline": "Stocks to Watch Thursday Recap: Walmart, Nvidia, Cracker Barrel, Regeneron",
      "id": 137566510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares closed up nearly 6.5%. ↘️Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.",
      "url": "https://finnhub.io/api/news?id=ca40a6252ab1270147bbf92f5beb6ed8ac409575b6400a168a7846e58af6bc29"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More",
    "summary": "Nvidia turns lower as strong earnings fail to assuage concerns over an artificial-intelligence bubble.",
    "url": "https://finnhub.io/api/news?id=4621cf73e0e38efb70dd9646ac5cae83374e6caa0fd216e82d3bead261a10230",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763673780,
      "headline": "These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More",
      "id": 137566437,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Nvidia turns lower as strong earnings fail to assuage concerns over an artificial-intelligence bubble.",
      "url": "https://finnhub.io/api/news?id=4621cf73e0e38efb70dd9646ac5cae83374e6caa0fd216e82d3bead261a10230"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C",
    "url": "https://finnhub.io/api/news?id=4917d2d9bc9b7224b02d3ecba954d37cb32fa3fd29efcf6972f39f52d51e1e43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763672010,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 137566589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C",
      "url": "https://finnhub.io/api/news?id=4917d2d9bc9b7224b02d3ecba954d37cb32fa3fd29efcf6972f39f52d51e1e43"
    }
  },
  {
    "ts": null,
    "headline": "Why Exact Sciences Rallied Over 50% This Week",
    "summary": "The company received a buyout offer from Abbot Labs.",
    "url": "https://finnhub.io/api/news?id=dc400ac7739fe71b5824e0cebfb60d7b182b1e6d2b740182e54462970e8f284d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763670682,
      "headline": "Why Exact Sciences Rallied Over 50% This Week",
      "id": 137566596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The company received a buyout offer from Abbot Labs.",
      "url": "https://finnhub.io/api/news?id=dc400ac7739fe71b5824e0cebfb60d7b182b1e6d2b740182e54462970e8f284d"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences",
    "summary": "Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow Abbott — which makes medical tests, baby formula and continuous glucose monitors, among other products — to enter the cancer testing space. Exact Sciences focuses on early cancer detection and personalized treatments, and ...",
    "url": "https://finnhub.io/api/news?id=e84531124cb05cfd9b80cb063c82784f18f0c28fe18edaaa9b3bc8aa5fb55dfe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763669280,
      "headline": "Abbott Laboratories announces $21 billion deal to buy Cologuard-maker Exact Sciences",
      "id": 137566597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow Abbott — which makes medical tests, baby formula and continuous glucose monitors, among other products — to enter the cancer testing space. Exact Sciences focuses on early cancer detection and personalized treatments, and ...",
      "url": "https://finnhub.io/api/news?id=e84531124cb05cfd9b80cb063c82784f18f0c28fe18edaaa9b3bc8aa5fb55dfe"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?",
    "summary": "Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.",
    "url": "https://finnhub.io/api/news?id=8b3e7d413dbb4f3a5a450952fb80b69042a296f4578ac91186fcef9025e33c9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763669033,
      "headline": "Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?",
      "id": 137566598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.",
      "url": "https://finnhub.io/api/news?id=8b3e7d413dbb4f3a5a450952fb80b69042a296f4578ac91186fcef9025e33c9a"
    }
  },
  {
    "ts": null,
    "headline": "Why Exact Sciences Stock Surged Today",
    "summary": "A healthcare giant covets the cancer screening leader's technology.",
    "url": "https://finnhub.io/api/news?id=8e2deba7490a47f0094dc34f62cf0e38a38eae70a06ccc0920efd11321fb27eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763668864,
      "headline": "Why Exact Sciences Stock Surged Today",
      "id": 137566599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "A healthcare giant covets the cancer screening leader's technology.",
      "url": "https://finnhub.io/api/news?id=8e2deba7490a47f0094dc34f62cf0e38a38eae70a06ccc0920efd11321fb27eb"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "0939 ET – Abbott’s commercial infrastructure makes it a good fit for Exact Sciences, TD Cowen analyst Joshua Jennings said in a report issued shortly before the deal was formerly announced earlier today.  “Abbott controls the largest primary care-facing point-of-care diagnostics footprint globally,” Jennings says.  Additionally, Abbott’s large salesforce for its continuous glucose monitor products could be leveraged to boost sales through the primary care provider channel.",
    "url": "https://finnhub.io/api/news?id=1470f1786a031e4c9f2f6eac3390d266fb15caed165661eae31879a9dec72b24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763659980,
      "headline": "Health Care Roundup: Market Talk",
      "id": 137563011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "0939 ET – Abbott’s commercial infrastructure makes it a good fit for Exact Sciences, TD Cowen analyst Joshua Jennings said in a report issued shortly before the deal was formerly announced earlier today.  “Abbott controls the largest primary care-facing point-of-care diagnostics footprint globally,” Jennings says.  Additionally, Abbott’s large salesforce for its continuous glucose monitor products could be leveraged to boost sales through the primary care provider channel.",
      "url": "https://finnhub.io/api/news?id=1470f1786a031e4c9f2f6eac3390d266fb15caed165661eae31879a9dec72b24"
    }
  },
  {
    "ts": null,
    "headline": "Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know",
    "summary": "Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer is a colonoscopy.",
    "url": "https://finnhub.io/api/news?id=8ea8e33e9114a6db72a478cf771f29d189c4820701653707ad3b7d93a2d6b6ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763658118,
      "headline": "Madison's Exact Sciences' $23 billion sale is tied to its Cologuard cancer test. What to know",
      "id": 137563012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Exact Sciences markets Cologuard as a non-invasive, convenient test. The traditional method of testing for colorectal cancer is a colonoscopy.",
      "url": "https://finnhub.io/api/news?id=8ea8e33e9114a6db72a478cf771f29d189c4820701653707ad3b7d93a2d6b6ae"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion",
    "summary": "The healthcare conglomerate  Abbott Laboratories  said on Thursday it would buy  Exact Sciences  makers of the at-home colon cancer test Cologuard, for roughly $21 billion.  The deal appears to be the biggest healthcare acquisition announced this the year, and would be Abbott’s largest since 2017.  Abbott will pay $105 per share of Exact Sciences, a 50% premium over Exact Sciences’ closing price on Tuesday of $69.68.",
    "url": "https://finnhub.io/api/news?id=c507bc8a22d3c7b1ad5f09ccfff27e27688c4a99bb0062c38f4ad507af363067",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763657460,
      "headline": "Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion",
      "id": 137563013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The healthcare conglomerate  Abbott Laboratories  said on Thursday it would buy  Exact Sciences  makers of the at-home colon cancer test Cologuard, for roughly $21 billion.  The deal appears to be the biggest healthcare acquisition announced this the year, and would be Abbott’s largest since 2017.  Abbott will pay $105 per share of Exact Sciences, a 50% premium over Exact Sciences’ closing price on Tuesday of $69.68.",
      "url": "https://finnhub.io/api/news?id=c507bc8a22d3c7b1ad5f09ccfff27e27688c4a99bb0062c38f4ad507af363067"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Nvidia's Strong Earnings Drive Overall Market Gains;",
    "summary": "All three major US stock indexes were up in late-morning trading after Nvidia (NVDA) reported strong",
    "url": "https://finnhub.io/api/news?id=2da60243bd0e65ea1c311af7902367fa22ef96eabc7316f57b0e33419bddcc93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763656345,
      "headline": "Top Midday Stories: Nvidia's Strong Earnings Drive Overall Market Gains;",
      "id": 137562957,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading after Nvidia (NVDA) reported strong",
      "url": "https://finnhub.io/api/news?id=2da60243bd0e65ea1c311af7902367fa22ef96eabc7316f57b0e33419bddcc93"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron",
    "summary": "↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares climbed 6%. ↗️ Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.",
    "url": "https://finnhub.io/api/news?id=2952b41960798b4ec3377c7e89a13a3a3e807e801fdbef5f5a90e096172d3d14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763652853,
      "headline": "Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron",
      "id": 137556189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares climbed 6%. ↗️ Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.",
      "url": "https://finnhub.io/api/news?id=2952b41960798b4ec3377c7e89a13a3a3e807e801fdbef5f5a90e096172d3d14"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Nvidia, Palantir, AMD, Palo Alto Networks, Walmart, Alphabet, and More",
    "summary": "Chip maker Nvidia’s strong earnings and rock-solid guidance ease worries about an artificial-intelligence bubble.",
    "url": "https://finnhub.io/api/news?id=8afee9562433309d691da2dd2afc121f72b4373c4d93bd1204eb6cd2c5d4a0d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763635080,
      "headline": "These Stocks Are Moving the Most Today: Nvidia, Palantir, AMD, Palo Alto Networks, Walmart, Alphabet, and More",
      "id": 137554168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Chip maker Nvidia’s strong earnings and rock-solid guidance ease worries about an artificial-intelligence bubble.",
      "url": "https://finnhub.io/api/news?id=8afee9562433309d691da2dd2afc121f72b4373c4d93bd1204eb6cd2c5d4a0d0"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Soars As Abbott Unveils $21 Billion Buyout",
    "summary": "Deal boosts ABT's cancer-screening footprint and long-term growth",
    "url": "https://finnhub.io/api/news?id=73b1e2f81d45c2297acbcdc0d70ec68f2f8958680cf40300a5d682e907fd8115",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763652069,
      "headline": "Exact Sciences Soars As Abbott Unveils $21 Billion Buyout",
      "id": 137556471,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Deal boosts ABT's cancer-screening footprint and long-term growth",
      "url": "https://finnhub.io/api/news?id=73b1e2f81d45c2297acbcdc0d70ec68f2f8958680cf40300a5d682e907fd8115"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Eyes Entry Into Cancer Diagnostics Space With $21 Billion Exact Sciences Buyout",
    "summary": "Abbott Laboratories (ABT) agreed to acquire cancer screening and diagnostics tests provider Exact Sc",
    "url": "https://finnhub.io/api/news?id=22857df49a26f1a1843be3ec5ad22dc51f509f9a8a63fb5452b3f01eca4201d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763651896,
      "headline": "Abbott Laboratories Eyes Entry Into Cancer Diagnostics Space With $21 Billion Exact Sciences Buyout",
      "id": 137556472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) agreed to acquire cancer screening and diagnostics tests provider Exact Sc",
      "url": "https://finnhub.io/api/news?id=22857df49a26f1a1843be3ec5ad22dc51f509f9a8a63fb5452b3f01eca4201d6"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Medical Device Innovations Affect Abbott Laboratories’ Valuation in 2025",
    "summary": "If you have ever wondered whether Abbott Laboratories is trading for more or less than its true value, you are in the right place. The stock has returned 11.2% year to date and 10.9% over the past 12 months, despite recent minor pullbacks of 2.1% in the last week and 2.6% in the last month. Recent headlines have focused on Abbott's continuous innovation in medical devices and its steady expansion into global healthcare markets. Industry analysts have also highlighted the company's strategic...",
    "url": "https://finnhub.io/api/news?id=6bf0693334e8b673d50b500a6ffa093846ec603b7b4711f15774a518b7fb0d3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763651872,
      "headline": "How Recent Medical Device Innovations Affect Abbott Laboratories’ Valuation in 2025",
      "id": 137556473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "If you have ever wondered whether Abbott Laboratories is trading for more or less than its true value, you are in the right place. The stock has returned 11.2% year to date and 10.9% over the past 12 months, despite recent minor pullbacks of 2.1% in the last week and 2.6% in the last month. Recent headlines have focused on Abbott's continuous innovation in medical devices and its steady expansion into global healthcare markets. Industry analysts have also highlighted the company's strategic...",
      "url": "https://finnhub.io/api/news?id=6bf0693334e8b673d50b500a6ffa093846ec603b7b4711f15774a518b7fb0d3e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott to buy Nasdaq-listed diagnostics firm in USD23 billion deal",
    "summary": "Abbott to buy Nasdaq-listed diagnostics firm in USD23 billion deal",
    "url": "https://finnhub.io/api/news?id=a7c056caf5b3161fd903dfe148f0b0d5ff27627814795ad9f77aff6d8a580f0d",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763651705,
      "headline": "Abbott to buy Nasdaq-listed diagnostics firm in USD23 billion deal",
      "id": 137556031,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a7c056caf5b3161fd903dfe148f0b0d5ff27627814795ad9f77aff6d8a580f0d"
    }
  },
  {
    "ts": null,
    "headline": "Abbott to Acquire Exact Sciences for $21 Billion",
    "summary": "Abbott Laboratories  agreed to acquire cancer diagnostics company  Exact Sciences  in a deal valued at about $21 billion, as Abbott looks to compete in the burgeoning market for multi-cancer early detection tests.  Exact Sciences shareholders will receive $105 a share.  The stock rose 17.9% to $101.60 in morning trading after closing at $86.18 Wednesday.",
    "url": "https://finnhub.io/api/news?id=7d6f37a201e2d8f5ce0b3fe44fdea738a95efcb23148867a3bb506364a99cc23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763651280,
      "headline": "Abbott to Acquire Exact Sciences for $21 Billion",
      "id": 137556474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories  agreed to acquire cancer diagnostics company  Exact Sciences  in a deal valued at about $21 billion, as Abbott looks to compete in the burgeoning market for multi-cancer early detection tests.  Exact Sciences shareholders will receive $105 a share.  The stock rose 17.9% to $101.60 in morning trading after closing at $86.18 Wednesday.",
      "url": "https://finnhub.io/api/news?id=7d6f37a201e2d8f5ce0b3fe44fdea738a95efcb23148867a3bb506364a99cc23"
    }
  },
  {
    "ts": null,
    "headline": "Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences",
    "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
    "url": "https://finnhub.io/api/news?id=235071ce77144fe548496766c101e4cbcf3d04ebb34739e6bbbc69a9fde920e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763649085,
      "headline": "Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences",
      "id": 137556475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "US healthcare group Abbott Laboratories has bet on rapid cancer testing to boost growth, striking a $23bn deal to buy Exact Sciences in its biggest...",
      "url": "https://finnhub.io/api/news?id=235071ce77144fe548496766c101e4cbcf3d04ebb34739e6bbbc69a9fde920e9"
    }
  },
  {
    "ts": null,
    "headline": "Abbott to buy Exact Sciences for $21B, Verizon to cut 13K jobs",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Abbott Laboratories' (ABT) move to buy Exact Sciences (EXAS) in a $21 billion deal, reports that Verizon Communications (VZ) will be cutting over 13,000 jobs in its restructuring, and Bath & Body Works (BBWI) shares sinking after the brand cut its full-year earnings forecast. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=158a3021c0e0f736ff1e0292e63fd7dc1cf454ec2c818f5397be14580d0175e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763648804,
      "headline": "Abbott to buy Exact Sciences for $21B, Verizon to cut 13K jobs",
      "id": 137556476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Abbott Laboratories' (ABT) move to buy Exact Sciences (EXAS) in a $21 billion deal, reports that Verizon Communications (VZ) will be cutting over 13,000 jobs in its restructuring, and Bath & Body Works (BBWI) shares sinking after the brand cut its full-year earnings forecast. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=158a3021c0e0f736ff1e0292e63fd7dc1cf454ec2c818f5397be14580d0175e5"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Catapults On $23 Billion Abbott Labs Buyout",
    "summary": "Exact Sciences stock rocketed for a second day Thursday, after Abbott Laboratories confirmed a $23 bil. buyout deal.",
    "url": "https://finnhub.io/api/news?id=7cce645ef4e528bd7c31d514b75d0ce63687b28cf6095efe9b1fb7d38d1b76b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763648646,
      "headline": "Exact Sciences Catapults On $23 Billion Abbott Labs Buyout",
      "id": 137556477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Exact Sciences stock rocketed for a second day Thursday, after Abbott Laboratories confirmed a $23 bil. buyout deal.",
      "url": "https://finnhub.io/api/news?id=7cce645ef4e528bd7c31d514b75d0ce63687b28cf6095efe9b1fb7d38d1b76b0"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.",
    "summary": "Shares of  Exact Sciences  rose sharply Thursday after  Abbott Laboratories  agreed to purchase the cancer screening company in a cash deal worth around $21 billion.  Exact Sciences  stockholders will receive $105 a share in the acquisition.  Abbott will also absorb Exact Sciences’ estimated $1.8 billion of net debt, for a total enterprise value of around $23 billion.",
    "url": "https://finnhub.io/api/news?id=f2792f8b8877f13b5f9f1356013127c11dcef7999dd71fef0d6fc6b4bfedb27f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763645040,
      "headline": "Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.",
      "id": 137556478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Shares of  Exact Sciences  rose sharply Thursday after  Abbott Laboratories  agreed to purchase the cancer screening company in a cash deal worth around $21 billion.  Exact Sciences  stockholders will receive $105 a share in the acquisition.  Abbott will also absorb Exact Sciences’ estimated $1.8 billion of net debt, for a total enterprise value of around $23 billion.",
      "url": "https://finnhub.io/api/news?id=f2792f8b8877f13b5f9f1356013127c11dcef7999dd71fef0d6fc6b4bfedb27f"
    }
  },
  {
    "ts": null,
    "headline": "Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know",
    "summary": "Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share. Click here to find out why ABT is a Hold.",
    "url": "https://finnhub.io/api/news?id=817653eb369ae112570310200e4d69fc79e7569a60b1bf1f393f99148246783d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763644705,
      "headline": "Abbott To Complete $21B M&A Deal For Exact Sciences - What Investors Should Know",
      "id": 137562632,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2197823180/image_2197823180.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share. Click here to find out why ABT is a Hold.",
      "url": "https://finnhub.io/api/news?id=817653eb369ae112570310200e4d69fc79e7569a60b1bf1f393f99148246783d"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences stock jumps after Abbott confirms acquisition",
    "summary": "Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal valued at approximately $21 billion.",
    "url": "https://finnhub.io/api/news?id=2719a8a072538fa7fce9830a0f1092beb541e35732de88956198ee362548519e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763644198,
      "headline": "Exact Sciences stock jumps after Abbott confirms acquisition",
      "id": 137556479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal valued at approximately $21 billion.",
      "url": "https://finnhub.io/api/news?id=2719a8a072538fa7fce9830a0f1092beb541e35732de88956198ee362548519e"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest moves midday: Nvidia, Exact Sciences, Walmart, Strategy, Regeneron & more",
    "summary": "These are some of the stocks posting the largest moves in midday trading.",
    "url": "https://finnhub.io/api/news?id=aae5f7e7a807e453f9e7237267d48d8dedf7a6ef5cdfc4dd7b899378776b3537",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643287,
      "headline": "Stocks making the biggest moves midday: Nvidia, Exact Sciences, Walmart, Strategy, Regeneron & more",
      "id": 137570215,
      "image": "https://image.cnbcfm.com/api/v1/image/108098120-1738791949909-gettyimages-2162970675-BITCOIN_2024.jpeg?v=1763660576&w=1920&h=1080",
      "related": "ABT",
      "source": "CNBC",
      "summary": "These are some of the stocks posting the largest moves in midday trading. ",
      "url": "https://finnhub.io/api/news?id=aae5f7e7a807e453f9e7237267d48d8dedf7a6ef5cdfc4dd7b899378776b3537"
    }
  },
  {
    "ts": null,
    "headline": "Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments",
    "summary": "Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.",
    "url": "https://finnhub.io/api/news?id=afe4d7eb6bb9ff33d0436acfb4ceb63a34b5c551faf6f72e9fd2ece9564a71bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763641800,
      "headline": "Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments",
      "id": 137556480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.",
      "url": "https://finnhub.io/api/news?id=afe4d7eb6bb9ff33d0436acfb4ceb63a34b5c551faf6f72e9fd2ece9564a71bb"
    }
  },
  {
    "ts": null,
    "headline": "BTIG Reiterates Abbott Laboratories (ABT) Buy Recommendation",
    "summary": "BTIG Reiterates Abbott Laboratories (ABT) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=7196cdee844f349633c98def8b734624bd0449d5159912c30a59b19b88435890",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763640201,
      "headline": "BTIG Reiterates Abbott Laboratories (ABT) Buy Recommendation",
      "id": 137555177,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7196cdee844f349633c98def8b734624bd0449d5159912c30a59b19b88435890"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports",
    "summary": "We recently published 10 Stocks Beating Wall Street at its Own Game. Exact Sciences Corp. (NASDAQ:EXAS) is one of the best-performing stocks on Wednesday. Exact Sciences climbed to a new two-year high on Wednesday, as investors loaded portfolios following reports that it set to be taken over by Abbott Laboratories in what could be its […]",
    "url": "https://finnhub.io/api/news?id=189371b24597da78acc2c7080d88978540bdd612f09304201cdcd9653a76e2c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763638035,
      "headline": "Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports",
      "id": 137556481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Beating Wall Street at its Own Game. Exact Sciences Corp. (NASDAQ:EXAS) is one of the best-performing stocks on Wednesday. Exact Sciences climbed to a new two-year high on Wednesday, as investors loaded portfolios following reports that it set to be taken over by Abbott Laboratories in what could be its […]",
      "url": "https://finnhub.io/api/news?id=189371b24597da78acc2c7080d88978540bdd612f09304201cdcd9653a76e2c1"
    }
  },
  {
    "ts": null,
    "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
    "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
    "url": "https://finnhub.io/api/news?id=be5320fdeae70f568f8619c0ea2b0af9be5f204d2cf7960957e2d60c174eb756",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763635860,
      "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
      "id": 137554467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
      "url": "https://finnhub.io/api/news?id=be5320fdeae70f568f8619c0ea2b0af9be5f204d2cf7960957e2d60c174eb756"
    }
  },
  {
    "ts": null,
    "headline": "Abbott to acquire Exact Sciences for about $21B",
    "summary": "The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early detection.",
    "url": "https://finnhub.io/api/news?id=e89cafca426a1e56870d04ac7d12864a8746770e9d9ed7a9fc9df0a39388baab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763631169,
      "headline": "Abbott to acquire Exact Sciences for about $21B",
      "id": 137556483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early detection.",
      "url": "https://finnhub.io/api/news?id=e89cafca426a1e56870d04ac7d12864a8746770e9d9ed7a9fc9df0a39388baab"
    }
  },
  {
    "ts": null,
    "headline": "Why Exact Sciences Stock Blasted Nearly 24% Higher Today",
    "summary": "A strategic investor is reportedly in advanced talks to purchase the company.",
    "url": "https://finnhub.io/api/news?id=0cda77e8ec277a1d6667dbf90d2a882a142b66345ced345acc09be6f0925711b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763598073,
      "headline": "Why Exact Sciences Stock Blasted Nearly 24% Higher Today",
      "id": 137554007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "A strategic investor is reportedly in advanced talks to purchase the company.",
      "url": "https://finnhub.io/api/news?id=0cda77e8ec277a1d6667dbf90d2a882a142b66345ced345acc09be6f0925711b"
    }
  }
]